A Study of Cardiovascular Events iN Diabetes Plus

NCT05441267 · Recruiting

Last updated 2026-05-28

This clinical trial is testing a new treatment in adults with type 2 diabetes to see how it affects the time until the first serious heart-related event occurs.

Status Recruiting Currently enrolling participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind prevention study

Participants 20,000 people Planned (estimated).

Who can join Ages 55+ · all sexes

Timeline Started 2023-03 · est. completion 2048-08

Where 1 site · United Kingdom

What this study is testing ClinicalTrials.gov NCT05441267 ↗

Description as written by the study sponsor.

ASCEND PLUS is testing whether, for people with type 2 diabetes who have not previously had a heart attack or stroke, regularly taking a tablet called semaglutide can safely help to reduce heart attacks, strokes, mini-strokes, the need for any procedures to unblock or bypass an artery to their heart, and the chance of dying because of vascular problems.

Treatments tested

Semaglutide Oral Tablet Drug

Oral semaglutide 14mg daily (option to reduce to 7mg daily)
Placebo oral tablet Drug

Placebo oral semaglutide

Main thing measured	Time to the first occurrence of a Major Adverse Cardiovascular Events (MACE+)
Sponsor	University of Oxford
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05441267 ↗